This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barter, P.J. Search for Related Content PubMed PubMed Citation Articles by Barter, P.J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease Related Collections Related Articles

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1305.)
© 2005 American Heart Association, Inc.

Editorials

Cardioprotective Effects of High-Density Lipoproteins

The Evidence Strengthens

P.J. Barter

From The Heart Research Institute, Sydney, Australia.

Correspondence to Philip Barter, The Heart Research Institute, 145 Missenden Road, Camperdown, NSW 2050, Australia. E-mail p.barter@hri.org.au

Key Words: HDL • atherosclerosis • inflammation

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The fact that a low level of high-density lipoprotein (HDL) cholesterol is highly predictive of future cardiovascular events has been established in population studies beyond all reasonable doubt. Furthermore, the evidence is overwhelming that the relationship is one of cause and effect rather than an epiphenomenon, with numerous studies in animals demonstrating that HDL-raising interventions translate into profound reductions in atherosclerosis. Such interventions have included the infusion of both native and reconstituted HDLs into rabbit models of atherosclerosis, the overexpression of apolipoprotein (apo) A-I (the major HDL protein) in transgenic mice and rabbits, and the inhibition of cholesteryl ester transfer protein (CETP) in rabbits.

See pages 1325 and 1426

Evidence that raising the level of HDLs is also antiatherogenic in humans is mounting, although there are still relatively few human studies that have directly tested the phenomenon. Fibrates, statins, and niacin all raise the level of HDL cholesterol, and treatment with each of these agents has been shown to be associated with a reduction in future cardiovascular events. Fibrates are especially effective in event reduction in people with insulin resistance or with other features of the metabolic syndrome, although the benefits cannot be explained in terms of the observed HDL raising.¹ Statins are effective in reducing events in all subjects, but the benefits can be explained almost completely in terms of the achieved LDL lowering²; the contribution of a statin-induced elevation of HDL is difficult to evaluate. Niacin, the most effective of the currently available HDL-raising agents, has also . . . [Full Text of this Article]

Related Articles:

Apolipoprotein A-I Mimetic Peptides

Mohamad Navab, G.M. Anantharamaiah, Srinivasa T. Reddy, Susan Hama, Greg Hough, Victor R. Grijalva, Nicholas Yu, Benjamin J. Ansell, Geeta Datta, David W. Garber, and Alan M. Fogelman
Arterioscler Thromb Vasc Biol 2005 25: 1325-1331. [Abstract] [Full Text] [PDF]

D-4F and Statins Synergize to Render HDL Antiinflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein E–Null Mice

Mohamad Navab, G.M. Anantharamaiah, Susan Hama, Greg Hough, Srinivasa T. Reddy, Joy S. Frank, David W. Garber, Shaila Handattu, and Alan M. Fogelman
Arterioscler Thromb Vasc Biol 2005 25: 1426-1432. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				S. Rashid, M. Marcil, I. Ruel, and J. Genest Identification of a novel human cellular HDL biosynthesis defect Eur. Heart J., September 2, 2009; 30(18): 2204 - 2212. [Abstract] [Full Text] [PDF]

				M. S Kramer, S. R Kahn, R. Rozen, R. Evans, R. W Platt, M. F. Chen, L. Goulet, L. Seguin, C. Dassa, J. Lydon, et al. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth Int. J. Epidemiol., June 1, 2009; 38(3): 715 - 723. [Abstract] [Full Text] [PDF]

				S. Shetty, E. R.M. Eckhardt, S. R. Post, and D. R. van der Westhuyzen Phosphatidylinositol-3-Kinase Regulates Scavenger Receptor Class B Type I Subcellular Localization and Selective Lipid Uptake in Hepatocytes Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2125 - 2131. [Abstract] [Full Text] [PDF]

				P. T. Duong, H. L. Collins, M. Nickel, S. Lund-Katz, G. H. Rothblat, and M. C. Phillips Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I J. Lipid Res., April 1, 2006; 47(4): 832 - 843. [Abstract] [Full Text] [PDF]